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on ECHO. PFTs showed stable spirometry but DLCO declined
after HCT (996 to 776, p¼0.02). Endocrine studies showed
high risk for gonadal dysfunction. Of males, 55% had normal
function, 33% were at high risk for hypogonadism and 11%
developed hypogonadism requiring therapy. Of females, 50%
had normal function and 50% developed ovarian failure
requiring therapy. Growth was monitored using bone age,
growth velocity and IGF-1. Patients with delayed growth
(35%) were able to normalized growth by 3 yrs. after HCT if
they did not have GVHD. Patients with GVHD had signiﬁcant
risk for continued delays. Bone density and DEXA scans
showed no signiﬁcant improvement in bone density and/or Z
score for whole body or lumbar spine after HCT. Risk for
osteoporosis or AVN were not decreased after HCT. In
summary, we show children with SCD with durable engraft-
ment after HCT are protected from sickle-related pathophys-
iologywith stabilization of renal, pulmonary, cardiac and CNS
dysfunction. Patients continue to be at risk for lung, bone and
gonadal damage due to HCT. To better understand the risks
associated with curative HCT we report one of the most
comprehensive systematic prospective long-term follow up
of pediatric patients that have undergone HCT for SCD.267
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Introduction: Systemic loxoscelism is a rare complication
from Loxosceles reclusa (brown recluse spider) envenomation
that occurs in children more often than adults. It is often difﬁ-
cult to diagnose and there is currently no standard treatment.
Symptoms can consist of localized skin necrosis, organ
dysfunction, hemolysis, systemic inﬂammation, and possible
death.Wepresentacaseof systemic loxoscelismthatpresented
with renal failure, hepatotoxicity, DIC, hemolytic anemia, and
secondary hemophagocytic lymphohistiocytosis (HLH).
Case Report: Our patient is a previously healthy 10 year old
male, who developed the acute onset of malaise, nausea,
fever, and a right elbow rash while attending camp in Ten-
nessee. Upon presentation to our emergency department
one day after the initiation of symptoms, he was noted to
have severe renal dysfunction, liver dysfunction, hemolytic
anemia, and thrombocytopenia. His physical exam was
signiﬁcant for fever and small, non-purulent blisters with
surrounding erythema in the right antecubital fossa. Further
investigation revealed elevation of soluble IL-2 receptor
(9204 units/ml), ferritin (>40,000 ng/ml), and triglycerides
(762 mg/dl) with hypoﬁbrinogenemia (102 mg/dl). A bone
marrow aspirate had moderate hemophagocytic activity
present. With continued worsening of his organ dysfunction,
hewas started on high dose dexamethasone therapy for HLH.
After initiation of steroid therapy, his organ dysfunction
resolved rapidly and hewas able to come off dialysis. His liver
dysfunction also resolved and his inﬂammatory markers
normalized. Investigation of his HLH did not reveal any
known disease causing mutations.
Discussion: The clinical course following brown recluse
spider bite can be relatively benign to life threatening with
severe organ dysfunction and systemic inﬂammation. Lox-
osceles venom contains pro-inﬂammatory proteins which
stimulate the production of interleukin-8, monocyte che-
moattractant protein-1, and granulocyte-macrophage
colony-stimulating factor all of which have been shown to beelevated in patients with HLH. Secondary HLH can be seen in
patients without an underlying genetic cause of the disease
and is often triggered by a concurrent medical condition.
Loxosceles envenomation should be considered as a potential
cause of secondary HLH.268
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The role of reduced intensity conditioning regimen and
impact of prior consolidation therapy with such regimens for
young adults with AML in CR1 remains controversial. At our
center from July 2005 to April 2012 we have done 52 allo-
geneic stem cell transplants for patients with acute myeloid
leukemia in CR1 using awell reported RIC regimen consisting
of Fludarabine andMelphalan. Majority of the donors (94.2%)
were HLA identical related donors. All patients received
a peripheral blood stem cell graft with a median CD34 cell
dose of 11x106/Kg. GVHD prophylaxis consisted of cyclo-
sporine combined with short course methotrexate. The
median age of the patients was 34 years (range: 11-63) and
there were 34 (65%) males. Majority (73%) were intermediate
risk patients. One patient died prior to engraftment while all
other cases engrafted with a median time to ANC>500/mm3
of 14 days and platelet count >20,000/mm3 was 16 days. 19
(36%) received an allogeneic SCT without any consolidation
therapy while the rest had consolidation therapy consisting
of either high dose cytarabine or cytarabine with an
anthracycline given for one, two or three cycles prior to
transplant. Repeated cycles of consolidation chemotherapy
were given in some cases mainly due to lack of a transplant
slots in the program, with intention to buy time prior to the
intended transplant. The treatment related mortality at 100
days was 3(5.7%) and at one year was 11(21%). Acute GVHD
grade II-IV was seen in 20(38%) and was grade III-IV in
10(19%). Chronic GVHD was seen in 29(55%) which was
extensive in 8(27%). Deaths attributable to GVHD (GVHD or
infection resulting from treatment of GVHD) occurred in 11
(21%). The 3 year KM-estimate of OS and EFS was 66.47.4%
and 61.97.5% respectively. Comparison of patients who did
not receive any consolidation therapy prior to transplant
(n¼19) versus those that received one or more consolidation
courses revealed that there was a signiﬁcantly improved OS
and a trend to improved EFS among those that received some
consolidation therapy (46.312.7% Vs.79.97.5% and
46.312.7% Vs. 71.78.7%; P-value ¼ 0.049 and 0.114
respectively). This data compared favorably with our
historical controls that received a conventional myeloa-
blative conditioning regimen (100 day and one year TRM ¼
16 % and 51% respectively). The OS and EFS was also signiﬁ-
cantly superior with the RIC conditioning regimen compared
to our myeloablative historical controls.
In conclusion allogeneic SCT with RIC regimens for young
adults with AML in CR1 results in clinical outcomes compa-
rable with those achieved by myeloablative regimens.
However, it would appear that some consolidation therapy
prior to RIC SCT is likely to improve the clinical outcome. The
optimal number and intensity of consolidation therapy
needs to be evaluated further in larger and prospective
clinical trials.
